Show simple item record

dc.contributor.authorDavis, Lisa E
dc.contributor.authorNicholls, Lauren A
dc.contributor.authorBabiker, Hani M
dc.contributor.authorLiau, Joy
dc.contributor.authorMahadevan, Daruka
dc.date.accessioned2019-10-09T16:43:00Z
dc.date.available2019-10-09T16:43:00Z
dc.date.issued2019-09-01
dc.identifier.citationDavis, L. E., Nicholls, L. A., Babiker, H. M., Liau, J., & Mahadevan, D. (2019). PD-1 Inhibition Achieves a Complete Metabolic Response in a Patient with Malignant Peripheral Nerve Sheath Tumor. Cancer immunology research, 7(9), 1396-1400.en_US
dc.identifier.issn2326-6066
dc.identifier.pmid31383651
dc.identifier.doi10.1158/2326-6066.CIR-19-0072
dc.identifier.urihttp://hdl.handle.net/10150/634697
dc.description.abstractHigh-grade malignant peripheral nerve sheath tumors (MPNST) have a poor prognosis with limited responsiveness to systemic therapy. We document a case of a complete metabolic response to pembrolizumab monotherapy in metastatic disease. Tumor molecular profiling identified programmed-death ligand-1 (PD-L1) positivity. This characteristic provided a rationale for immune-checkpoint therapy. Treatment with pembrolizumab resulted in a complete metabolic response after four cycles of therapy. Patients with PD-L1-positive, metastatic MPNST may be candidates for immune-checkpoint therapy, which may produce a durable completere mission. Future study of anti-PD-1/PD-L1 therapy is warranted.en_US
dc.description.sponsorshipCCSG P30 supplement from the NCIen_US
dc.language.isoenen_US
dc.publisherAMER ASSOC CANCER RESEARCHen_US
dc.rightsCopyright © 2019 American Association for Cancer Research.en_US
dc.titlePD-1 Inhibition Achieves a Complete Metabolic Response in a Patient with Malignant Peripheral Nerve Sheath Tumoren_US
dc.typeArticleen_US
dc.contributor.departmentUniv Arizona, Coll Pharm, Dept Pharm Practice & Scien_US
dc.contributor.departmentUniv Arizona, Ctr Cancen_US
dc.contributor.departmentUniv Arizona, Coll Med, Dept Meden_US
dc.contributor.departmentUniv Arizona, Coll Med, Dept Med Imagingen_US
dc.identifier.journalCANCER IMMUNOLOGY RESEARCHen_US
dc.description.note12 month embargo; published online: 1 September 2019en_US
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en_US
dc.eprint.versionFinal accepted manuscripten_US
dc.source.journaltitleCancer immunology research


Files in this item

Thumbnail
Name:
Revised CIR-19-0072R-FINAL.pdf
Embargo:
2020-09-01
Size:
1.144Mb
Format:
PDF
Description:
Final Accepted Manuscript

This item appears in the following Collection(s)

Show simple item record